Skip to search formSkip to main contentSkip to account menu

GFT505

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Nonalcoholic fatty liver disease (NAFLD) is currently the most common liver disease worldwide, the prevalence of which had… 
2014
2014
We report here the efficacy and safety of GFT505, a novel liver-targeted peroxisome proliferator-activated receptor alpha/delta… 
Review
2014
Review
2014
Introduction: PPARs are nuclear receptors that play key roles in the regulation of metabolism and inflammation. GFT505 is a new… 
Highly Cited
2013
Highly Cited
2013
OBJECTIVE The development of new insulin sensitizers is an unmet need for the treatment of type 2 diabetes. We investigated the… 
Highly Cited
2013
Highly Cited
2013
Nonalcoholic fatty liver disease (NAFLD) covers a spectrum of liver damage ranging from simple steatosis to nonalcoholic… 
Review
2013
Review
2013
  • J. Fruchart
  • Cardiovascular Diabetology
  • 2013
  • Corpus ID: 5776869
Dyslipidemia is a major risk factor for cardiovascular (CV) disease – the primary cause of death, worldwide. Although reducing… 
Highly Cited
2011
Highly Cited
2011
OBJECTIVE We evaluated the metabolic effects and tolerability of GFT505, a novel dual peroxisome proliferator–activated receptor… 
2011
2011
RESEARCH DESIGN AND METHODSdThe S1 study was conducted in 94 patients with combined dyslipidemia while the S2 study was conducted…